Strata Critical Medical Future Growth
Future criteria checks 4/6
Strata Critical Medical is forecast to grow earnings and revenue by 161.7% and 15.9% per annum respectively while EPS is expected to grow by 161.7% per annum.
Key information
161.7%
Earnings growth rate
161.71%
EPS growth rate
| Healthcare earnings growth | 17.4% |
| Revenue growth rate | 15.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 05 Aug 2026 |
Recent future growth updates
Analysis Article • Aug 07
Analysts Are Updating Their Strata Critical Medical, Inc. (NASDAQ:SRTA) Estimates After Its Second-Quarter Results
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 9.8% to close at US$5.59...Analysis Article • May 08
Strata Critical Medical, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 6.4% to close at US$5.34...Recent updates
Analysis Article • Aug 07
Analysts Are Updating Their Strata Critical Medical, Inc. (NASDAQ:SRTA) Estimates After Its Second-Quarter Results
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 9.8% to close at US$5.59...
Narrative Update • Aug 06
SRTA: Higher 2026 Guidance And Index Inclusion Will Support Future Upside
Analysts have lifted their price target for Strata Critical Medical from $11.50 to $12.75, citing updated assumptions for revenue growth, profit margin and future P/E as the key drivers of this change. What’s in the News for Strata Critical Medical Strata Critical Medical raised its earnings guidance for 2026 and now expects revenue of US$285 million to US$295 million, compared with the previous range of US$260 million to US$275 million.Seeking Alpha • Jul 07
Strata Critical Medical: A Better Alternative To TransMedics In Organ Transplant Logistics
Summary Strata Critical Medical is rated a buy, driven by expanding market share, operational efficiencies, and a comprehensive suite of transplant logistics and clinical services. SRTA's asset-light-to-moderate model, strategic acquisitions, and focus on NRP technology position it to benefit from industry consolidation and secular tailwinds. Gross margin improvement is a key near-term catalyst, with management incentivized to reach 25% margins by 2027; Q1 2026 gross margin reached 21%. TransMedics faces slowing growth, margin compression, and competitive headwinds, leading to a hold rating as TMDX's market share and valuation multiples are expected to converge with SRTA. Read the full article on Seeking Alpha
Narrative Update • Jun 22
SRTA: Index Inclusion And 2026 Guidance Reaffirmation Will Support Future Upside
Analysts have raised their price target on Strata Critical Medical by $0.25, citing updated assumptions that include slightly higher projected revenue growth, stronger profit margins, and a lower future P/E multiple, which together support a modestly higher valuation. Analyst Commentary Recent Street research around Strata Critical Medical highlights a mix of optimism about the company’s potential and a more cautious tone around how much of that potential is already reflected in the valuation.Narrative Update • Jun 07
SRTA: Fresh Bullish Coverage And 2026 Guidance Will Support Future Upside
Narrative Update: Strata Critical Medical The analyst price target for Strata Critical Medical has moved from $11.25 to $11.50. Analysts point to fresh bullish coverage and updated assumptions on revenue growth, profit margins and future P/E multiples as key drivers of the change.
Narrative Update • May 24
SRTA: Bullish Coverage And 2026 Revenue Guidance May Support Future Upside
Strata Critical Medical's updated analyst price target has moved to $9.13 from $8.81, as analysts point to revised assumptions around growth, margins, and future P/E expectations following recent bullish coverage and a $0.25 increase in one firm's target. Analyst Commentary Recent Street research on Strata Critical Medical has leaned positive, with several firms initiating bullish coverage and one lifting its price target by $0.25.Analysis Article • May 08
Strata Critical Medical, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 6.4% to close at US$5.34...Narrative Update • May 08
SRTA: Higher 2026 Guidance And Mixed Risk Signals Will Support Future Upside
Analysts have nudged their average price target for Strata Critical Medical higher by $0.25, reflecting a slightly stronger profit outlook and updated P/E assumptions. At the same time, they have tempered revenue growth expectations and applied a modestly higher discount rate.Narrative Update • Apr 20
SRTA: Bullish Execution On Raised 2026 Revenue Outlook May Unlock Future Upside
The Analyst Price Target for Strata Critical Medical has been revised from $9.63 to $8.81, with analysts pointing to updated assumptions on revenue growth, profit margins, and a higher forward P/E multiple, despite generally bullish recent coverage. Analyst Commentary Recent research coverage on Strata Critical Medical has been largely constructive, with analysts updating their models to reflect revised assumptions on revenue, margins, and valuation multiples.Narrative Update • Apr 06
SRTA: Raised Revenue Outlook And Richer Future P/E Will Support Upside
Analysts have raised their price target on Strata Critical Medical to $8.00 per share, citing updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, supported by recent bullish initiation reports from multiple firms. Analyst Commentary Recent bullish initiation reports on Strata Critical Medical highlight constructive views on the company’s long term prospects, but not all commentary is aligned with that optimism.Narrative Update • Mar 23
SRTA: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their price target on Strata Critical Medical to $8.00. This reflects updated assumptions for significantly higher revenue growth, lower profit margins, and a substantially higher future P/E multiple.Narrative Update • Mar 09
SRTA: Higher Revenue Outlook And Impairment Charge Will Support Future Upside
Analysts have adjusted their price target on Strata Critical Medical to $9.63, reflecting updated assumptions that combine a different discount rate and future P/E with materially higher modeled revenue growth and slightly lower profit margins. What's in the News Strata Critical Medical raised its 2026 revenue guidance to a range of $260 million to $275 million, compared with the prior range of $255 million to $270 million (Key Developments).Narrative Update • Feb 22
SRTA: Higher Margin Outlook Will Support Future Earnings Power
Analysts have adjusted their price target on Strata Critical Medical to $8.00, reflecting updated assumptions for slightly higher revenue, improved profit margins, a modestly higher discount rate, and a lower future P/E multiple. Valuation Changes Fair Value: $8.00 stays unchanged, with the revised assumptions still pointing to the same central estimate.Narrative Update • Feb 07
SRTA: Higher Margins And Updated Guidance Will Support Stronger Future Returns
Analysts have modestly reset their price target for Strata Critical Medical to $11.25, citing updated assumptions around slightly higher revenue growth, tighter profit margins at 18.60% and a lower future P/E of about 25.74x as key drivers of the revised view. What's in the News Strata Critical Medical issued earnings guidance for 2026, expecting revenue between $255 million and $270 million.Narrative Update • Jan 24
SRTA: Higher Margin Outlook And Revenue Guidance Will Support Earnings Power
Analysts have adjusted their price target on Strata Critical Medical to $8.00. The updated view reflects slightly different assumptions around revenue growth, profit margin and future P/E that they see as better aligning with their current outlook for the business.Narrative Update • Jan 09
SRTA: Higher Margin Outlook Will Drive Stronger Earnings Power Ahead
Analysts have raised their fair value estimate for Strata Critical Medical from $5.00 to $8.00, citing updated assumptions that include a lower discount rate, a revised outlook for revenue growth, higher expected profit margins, and a reduced future P/E multiple. What's in the News Strata Critical Medical issued earnings guidance for 2026, with expected revenue in a range of $255 million to $270 million.Analysis Article • Jan 06
Strata Critical Medical, Inc.'s (NASDAQ:SRTA) 30% Price Boost Is Out Of Tune With Revenues
Strata Critical Medical, Inc. ( NASDAQ:SRTA ) shares have had a really impressive month, gaining 30% after a shaky...Narrative Update • Dec 17
SRTA: Lower Risk Profile And Rising Margins Will Drive Stronger Future Returns
Analysts have raised their price target for Strata Critical Medical from 6.50 dollars to 11.25 dollars, citing a lower perceived risk profile and materially stronger long term profitability expectations, despite moderating revenue growth assumptions and a slightly lower future P E multiple. What's in the News Strata Critical Medical issued 2026 revenue guidance, forecasting between 255 million dollars and 270 million dollars.Narrative Update • Dec 03
SRTA: Keystone Acquisition Will Drive Expanded Cash Deployment And Future Earnings Upside
Analysts have nudged their price target on Strata Critical Medical higher to $9.63 from $9.25, citing the strategically accretive Keystone Perfusion Services acquisition and the company’s more constructive growth outlook as key drivers. Analyst Commentary Bullish analysts view the Keystone Perfusion Services acquisition as a strategically important use of Strata Critical Medical's sizable cash balance.Narrative Update • Nov 19
SRTA: Keystone Acquisition Will Drive Material Revenue Expansion And Lower Risk
Analysts have raised their price target for Strata Critical Medical to $7.25, up from $6.50. They cite strong support for the company's recent acquisition of Keystone Perfusion Services as a strategic use of its significant cash reserves.Narrative Update • Nov 03
SRTA: Cash Deployment Through Acquisition Will Drive Expansion In Healthcare Reach
Analysts have raised their price target for Strata Critical Medical to $9.25, up from $7.83. They cited stronger strategic deployment of cash resources with the acquisition of Keystone Perfusion Services and improved expectations for future performance.Narrative Update • Sep 23
Critical Organ Transport And Joby Aviation Will Expand Healthcare Reach
Strata Critical Medical’s consensus price target has risen from $5.83 to $7.83, as analysts express increased confidence in management’s ability to deploy capital efficiently and drive shareholder value following the accretive acquisition of Keystone Perfusion Services. Analyst Commentary Bullish analysts highlight the successful deployment of Strata's large $235M pro forma cash position through the acquisition of Keystone Perfusion Services for $124M.Narrative Update • Aug 06
Critical Organ Transport And Joby Aviation Will Expand Healthcare Reach
The consensus analyst price target for Blade Air Mobility has increased, primarily driven by higher revenue growth forecasts and a rising future P/E, bringing the fair value estimate up from $7.20 to $7.75. What's in the News Joby Aviation is exploring an acquisition of Blade Air Mobility to access a ready customer base for electric air taxis; no final decision has been made.Analysis Article • May 15
Earnings Release: Here's Why Analysts Cut Their Blade Air Mobility, Inc. (NASDAQ:BLDE) Price Target To US$7.20
Blade Air Mobility, Inc. ( NASDAQ:BLDE ) investors will be delighted, with the company turning in some strong numbers...Analysis Article • May 13
Blade Air Mobility, Inc. (NASDAQ:BLDE) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Those holding Blade Air Mobility, Inc. ( NASDAQ:BLDE ) shares would be relieved that the share price has rebounded 29...
New Narrative • Mar 31
eVTOL And Urban Air Mobility Will Open New Routes
Transition to electric vertical aircraft (eVTOL) promises long-term growth by enabling new routes and attracting a wider customer base.Seeking Alpha • Feb 26
Blade Air Mobility: Organ Transport Growth Now, eVTOL Growth Later
Summary Blade currently focuses on organ transport and passenger transport. The company is expanding in the organ logistics market. New perfusion technologies and competition provide a risk to the business. Air taxi services using eVTOLs provide a margin expansion opportunity. The stock is a speculative buy at this point. Read the full article on Seeking AlphaAnalysis Article • Nov 30
Revenues Not Telling The Story For Blade Air Mobility, Inc. (NASDAQ:BLDE) After Shares Rise 27%
Despite an already strong run, Blade Air Mobility, Inc. ( NASDAQ:BLDE ) shares have been powering on, with a gain of...Seeking Alpha • Nov 18
Blade: Transition To Profitability Should Provide Support Going Forward
Summary Blade's growth was weak in Q3, largely due to the company abandoning activities with marginal economics. Policy reforms and new technologies are driving growth in transplant volumes and transportation distances but competition is likely to increase in coming quarters. Provided Blade's margins continue to improve, the stock should move higher at some point. This will likely require an improvement in growth though. eVTOLs should provide Blade's passenger segment with a significant boost but this remains several years away. Read the full article on Seeking AlphaAnalysis Article • Nov 15
Analysts Have Made A Financial Statement On Blade Air Mobility, Inc.'s (NASDAQ:BLDE) Third-Quarter Report
Last week, you might have seen that Blade Air Mobility, Inc. ( NASDAQ:BLDE ) released its third-quarter result to the...Analysis Article • Sep 16
Blade Air Mobility, Inc.'s (NASDAQ:BLDE) Business Is Trailing The Industry But Its Shares Aren't
When you see that almost half of the companies in the Airlines industry in the United States have price-to-sales ratios...Seeking Alpha • Aug 15
Blade: Margins Remain An Issue
Summary Blade Air Mobility, Inc.'s business continues to expand, but revenue growth is being dampened by the company's decision to discontinue unprofitable activities. Competition from TransMedics poses a threat, and this issue is likely to come to a head in coming quarters. While Blade has managed to reduce its losses, stock-based compensation is causing fairly significant dilution. Blade's low valuation could be an opportunity, but the company probably needs to stabilize its growth and address dilution before the stock moves higher. Read the full article on Seeking AlphaAnalysis Article • Jun 19
Here's Why We're Not At All Concerned With Blade Air Mobility's (NASDAQ:BLDE) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • May 16
Blade Air Mobility: No Signs Of Competition Yet
Summary Rising organ transportation competition poses a threat to Blade's Medical segment, but Q1 revenue suggests there hasn't been a material impact so far. TransMedics' strong logistics growth and aggressive expansion plan put Blade and TransMedics on a collision course in coming years. Blade's valuation is low though, and if the Medical segment continues to grow or eVTOLs expand the UAM market, the stock could perform well. Read the full article on Seeking AlphaAnalysis Article • May 10
Analysts Are Updating Their Blade Air Mobility, Inc. (NASDAQ:BLDE) Estimates After Its First-Quarter Results
Blade Air Mobility, Inc. ( NASDAQ:BLDE ) defied analyst predictions to release its first-quarter results, which were...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 326 | 7 | N/A | 40 | 3 |
| 12/31/2026 | 287 | -5 | 19 | 28 | 4 |
| 6/30/2026 | 256 | -23 | -50 | -36 | N/A |
| 3/31/2026 | 229 | -16 | -58 | -45 | N/A |
| 12/31/2025 | 197 | -20 | -60 | -49 | N/A |
| 9/30/2025 | 167 | -22 | -56 | -42 | N/A |
| 6/30/2025 | 154 | -18 | -19 | 1 | N/A |
| 3/31/2025 | 131 | -14 | -22 | 13 | N/A |
| 12/31/2024 | 147 | -16 | -35 | -3 | N/A |
| 9/30/2024 | 158 | -43 | -38 | -10 | N/A |
| 6/30/2024 | 193 | -37 | -33 | -14 | N/A |
| 3/31/2024 | 231 | -50 | -34 | -31 | N/A |
| 12/31/2023 | 225 | -56 | -34 | -32 | N/A |
| 9/30/2023 | 216 | -38 | -34 | -32 | N/A |
| 6/30/2023 | 190 | -47 | -42 | -41 | N/A |
| 3/31/2023 | 165 | -26 | -45 | -44 | N/A |
| 12/31/2022 | 146 | -27 | -38 | -37 | N/A |
| 9/30/2022 | 133 | -11 | -47 | -34 | N/A |
| 6/30/2022 | 107 | -11 | -47 | -33 | N/A |
| 3/31/2022 | 85 | -44 | -44 | -31 | N/A |
| 12/31/2021 | 67 | -37 | -34 | -22 | N/A |
| 9/30/2021 | 51 | -40 | -16 | -16 | N/A |
| 6/30/2021 | 39 | -32 | -11 | -11 | N/A |
| 3/31/2021 | 29 | -9 | -3 | -2 | N/A |
| 12/31/2020 | 26 | -8 | -7 | -6 | N/A |
| 9/30/2020 | 23 | -10 | -11 | -11 | N/A |
| 9/30/2019 | 31 | -11 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRTA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).
Earnings vs Market: SRTA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SRTA is expected to become profitable in the next 3 years.
Revenue vs Market: SRTA's revenue (15.9% per year) is forecast to grow faster than the US market (13% per year).
High Growth Revenue: SRTA's revenue (15.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SRTA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/09 10:20 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Strata Critical Medical, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Itay Michaeli | Citigroup Inc |
| William Bonello | Craig-Hallum Capital Group LLC |